Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study
-
Published:2021-12
Issue:
Volume:5
Page:112-120
-
ISSN:2666-3287
-
Container-title:JAAD International
-
language:en
-
Short-container-title:JAAD International
Author:
Dousset Léa,
Pacaud Alize,
Barnetche Thomas,
Kostine Marie,
Dutriaux Caroline,
Pham-Ledard Anne,
Beylot-Barry Marie,
Gérard Emilie,
Prey Sorilla,
Andreu Nicolas,
Boniface Katia,
Seneschal JulienORCID
Reference28 articles.
1. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial;Hodi;Lancet Oncol,2018
2. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study;Robert;Lancet Oncol,2019
3. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes;Freeman-Keller;Clin Cancer Res,2016
4. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis;Teulings;J Clin Oncol,2015
5. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab;Hua;JAMA Dermatol,2016
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献